HOUSTON — The dual GLP-1/GIP receptor agonist tirzepatide showed significantly greater efficacy than the GLP-1 dulaglutide in the treatment of major kidney outcomes in patients with type 2 diabetes ...

A prespecified analysis of the SURPASS CVOT trial examining patients with high-risk CKD suggested tirzepatide reduces the risk of major kidney events, particularly eGFR decline and albuminuria, ...

Semaglutide, tirzepatide, and dulaglutide have similar gastrointestinal safety profiles among patients with type 2 diabetes (T2D), an active-comparator cohort study showed. “We were somewhat surprised ...

ATLANTA -- Use of GLP-1 receptor agonists was associated with a lower risk of mortality for dialysis patients with type 2 diabetes, according to a retrospective cohort study of Medicare enrollees.

A large cohort study found three popular GLP-1-based diabetes drugs -- semaglutide, dulaglutide, and tirzepatide -- carry similar risks for serious adverse GI events, with a rate of about 12 per 1,000 ...

About The Study: In this comparative effectiveness study in veterans with diabetes, liraglutide, semaglutide, and dulaglutide initiators had similar risks for kidney and cardiovascular outcomes.